Brainstorm Cell Therapeutics (NASDAQ:BCLI) Share Price Passes Above 200 Day Moving Average – Here’s What Happened

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s stock price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.67 and traded as high as $0.90. Brainstorm Cell Therapeutics shares last traded at $0.8710, with a volume of 11,992 shares traded.

Brainstorm Cell Therapeutics Stock Up 0.7%

The company has a market cap of $9.61 million, a P/E ratio of -0.26 and a beta of 0.48. The business has a fifty day moving average price of $0.75 and a 200-day moving average price of $0.67.

About Brainstorm Cell Therapeutics

BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.

The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).